Acquisitions (Tables)

6 Months Ended

Jun. 30, 2015

The purchase price consisted of the following amounts:



Fair market value of common stock issued	$	12,994
Estimate of potential contingent consideration⁽¹⁾	540
Total purchase price	$	13,534

⁽¹⁾

The amount of the contingent consideration reflected in the table above reflects our estimate, as of June 30, 2015, of the amount of contingent consideration that we will be required to pay to the former shareholders of FSH pursuant to the purchase agreement to acquire FSH and it subsidiaries. The contingent consideration will be paid out in additional shares of our stock based on the 180 day average of the closing price of our stock in the 180 days immediately prior to the one year anniversary of the closing of the acquisition. The contingent consideration will be measured at each reporting date with changes in its fair value recognized in our Unaudited Consolidated Statements of Comprehensive Income.

Schedule of Purchase Price Allocation

The initial purchase price allocation is as follows:



Cash	$	14,467
Investments	5,588
Premium and Agents' Receivable	1,496
Intangible assets	6,312
Goodwill	4,196
Other assets	609
Loss reserves	(2,390		)
Unearned premiums	(9,646		)
Reinsurance payable	(998		)
Loans payable	(2,246		)
Deferred taxes	(2,182		)
Other liabilities	(1,672		)
Total purchase price	$	13,534

Schedule of Pro Forma Information

The unaudited pro forma information has been prepared as if the FSH acquisition had taken place on January 1, 2015. The unaudited pro forma information is not necessarily indicative of the results that we would have achieved had the transaction taken place on January 1, 2015, and the unaudited pro forma information does not purport to be indicative of future financial operating results.



	For the Six Months Ended June 30, 2015
			Pro Forma
	As Reported		Adjustments		Pro Forma
Revenues	$	167,736	$	1,127	$	168,863

Net income	$	5,473	$	77	$	5,550

Diluted earnings per share	$	0.26	$	—	$	0.26